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Purpose: Pooled data were analyzed to evaluate the safety and tolerability of indacaterol, a 
once-daily inhaled long-acting β2-agonist for chronic obstructive pulmonary disease (COPD).
Patients and methods: Data were pooled from clinical studies of 3–12 months’ duration in 
patients with moderate-to-severe COPD receiving double-blind indacaterol 75 µg (n = 449), 
150 µg (n = 2611), 300 µg (n = 1157), or 600 µg once daily (n = 547); formoterol 12 µg twice 
daily (n = 556); salmeterol 50 µg twice daily (n = 895); placebo (n = 2012); or tiotropium 18 µg 
once daily, given open label or blinded (n = 1214). Outcomes were adverse events, serious adverse 
events and deaths, plasma potassium, blood glucose, and QTc interval and vital signs.
Results: The commonest adverse events with indacaterol were COPD worsening, 
nasopharyngitis, and headache; most cases were mild or moderate and incidence was generally 
similar to placebo and other active treatments. The risk of acute respiratory serious adverse 
events (leading to hospitalization, intubation, or death) was not significantly increased with 
any of the active treatments compared with placebo. COPD exacerbation rates (analyzed in 
the intent-to-treat population) were significantly reduced with all active treatments versus 
placebo. Hazard ratios versus placebo for major cardiovascular adverse events were ,1 for 
all indacaterol doses. Notable values for vital signs and measures of systemic β2-adrenoceptor 
activity were rare with indacaterol. The number of deaths adjusted per patient-year was lower 
with indacaterol (all doses combined) than with placebo (relative risk 0.21 [95% confidence 
interval 0.07–0.660], P = 0.008).
Conclusion: Indacaterol has a good profile of safety and tolerability that is appropriate for the 
maintenance treatment of patients with COPD.
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Introduction
Regular maintenance treatment with one or more long-acting bronchodilators is 
recommended for patients with moderate or more severe chronic obstructive pulmonary 
disease (COPD) to provide improved symptom control beyond that achieved with 
short-acting bronchodilators alone.1 Two classes of long-acting inhaled bronchodilators 
are currently available, the once-daily anticholinergic, tiotropium, and the long-acting 
β2-agonists (LABAs), taken either twice daily (formoterol and salmeterol) or once 
daily (indacaterol).
Clinical studies with indacaterol have reported 24-hour bronchodilator efficacy 
and improved clinical outcomes in the form of reduced symptoms and better health 
status. These studies also reported reassuring safety and tolerability data with doses up 
to and including 600 µg once daily, double the highest licensed dose, given for up to 
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1 year.2–6 As the first once-daily inhaled β2-agonist licensed 
for the treatment of COPD, it is relevant to scrutinize the 
safety of indacaterol, especially when many patients with 
COPD are elderly and comorbid conditions are common.7–9 
Here, an analysis of pooled safety data from recent clinical 
trials with indacaterol, providing a large patient population 
in which potential safety signals can be more robustly and 
comprehensively assessed compared with single studies, is 
reported. This pooled data set allows the safety of indacaterol 
to be compared with placebo and with data from formoterol, 
salmeterol, and tiotropium treatment groups.
Methods
This evaluation of safety data from the indacaterol clinical 
development program includes data from all completed 
indacaterol studies of at least 12 weeks in duration in COPD 
patients. Data were pooled from eleven randomized, double-
blind clinical studies: a 52-week study of indacaterol 300 µg 
and 600 µg, formoterol 12 µg, and placebo;3 a 26-week study 
of indacaterol 150 µg and 300 µg, placebo, and open-label 
tiotropium 18 µg4 and an extension of this study providing 
data on 52 weeks of treatment with indacaterol 150 µg and 
300 µg and placebo;6 a 26-week comparison of indacaterol 
150 µg, salmeterol 50 µg, and placebo;5 a 12-week 
  comparison of indacaterol 150 µg and placebo;2 two 12-week 
studies comparing indacaterol 150 µg with salmeterol10 or 
tiotropium;11 two 12-week studies comparing indacaterol 
75 µg with placebo;12 and two pan-Asian studies of 12 and 
26 weeks, comparing indacaterol 150 µg and 300 µg and 
placebo13 (one unpublished; see ClinicalTrials.gov identi-
fier NCT00792805). Data from additional treatment arms 
(indacaterol 75 µg and 600 µg and formoterol 12 µg twice 
daily) in an initial dose-finding stage of one study are also 
included.14 Indacaterol and tiotropium were taken once 
daily, salmeterol and formoterol twice daily. Further details 
of the eleven studies are provided in Table S1. A further 
analysis was undertaken specifically to look for any effect of 
  treatment on acute respiratory serious adverse events. For this 
purpose, data were analyzed from all blinded studies (23 in 
total) in COPD patients of at least 7 days’ duration in which 
indacaterol was taken via single-dose dry powder inhaler; 
only data from blinded treatments were included.
Assessments and outcomes
All the studies collected information on adverse events, 
  serious adverse events, and deaths (a subset of serious adverse 
events). An adverse event was defined as the appearance or 
worsening of any undesirable sign, symptom, or medical 
condition occurring after starting the study. Adverse events 
were categorized using the Medical Dictionary for   Regulatory 
Activities (MedDRA), the clinically validated, international 
medical terminology used by regulatory authorities and the 
pharmaceutical industry in the USA and EU. MedDRA is 
organized in different levels, from “system organ class” down 
to “preferred terms” for individual adverse events. Because 
of the overlap between related preferred terms, the terms 
may also be arranged in groups of terms relevant to a defined 
medical condition or area of interest, known as standardized 
MedDRA query groups.
The preferred term “COPD” is described here as “COPD 
worsening.” Although this term captured any   exacerbations, 
it also included events of any severity described as 
“worsening of COPD” and thus lacks sufficient rigor to 
merit the description “exacerbations.” Several of the studies 
in this safety evaluation did analyze COPD exacerbations 
that were defined and recorded separately from “COPD 
worsening” as an adverse event. For this analysis, a “COPD 
exacerbation” was defined as the onset or worsening of more 
than one respiratory symptom (ie, dyspnea, cough, sputum 
purulence or volume, or wheeze) for more than 3 consecutive 
days, plus a documented change in COPD-related treatment 
due to worsening symptoms (eg, corticosteroids, antibiotics, 
oxygen), and/or a documented COPD-related hospitaliza-
tion or emergency room visit. In later studies,10–12,15 the 
definition was updated to a worsening of two or more major 
symptoms (dyspnea, sputum volume and sputum purulence) 
for $2 consecutive days that required treatment with corti-
costeroids and/or antibiotics, or a worsening of any one of 
those symptoms plus any one minor symptom (sore throat, 
colds, fever without other cause, increased cough, increased 
wheeze) for $2 consecutive days that required treatment 
with corticosteroids and/or antibiotics. To better understand 
the profile of cardiovascular safety, additional analyses were 
performed using a predefined search for “major adverse 
cardiovascular events” (MACE). The MACE search was 
devised by the Division of Metabolism and Endocrinology 
Products at the US Food and Drug Administration (FDA) 
to analyze potential cardiovascular and cerebrovascular 
risks for new therapies.16 There are two MACE searches: 
(1) a broad search including all preferred terms relating to 
myocardial infarction, cerebrovascular events, and nervous 
system hemorrhages; and (2) a custom MACE (a subset 
of broad MACE), in which the search terms were selected 
by FDA medical reviewers to best match those referring to 
myocardial infarction and stroke. (For the terms used, see 
Tables S3 and S4 in the Supplementary material.) All fatal 
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study), and a clinical diagnosis of moderate-to-severe COPD 
defined according to Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) guidelines in 2005 or 2007; ie, 
post-bronchodilator forced expiratory volume in 1 second 
(FEV1) ,80% and $30% of the predicted normal value, 
and post-bronchodilator FEV1/forced vital capacity ,70% 
(post-bronchodilator referring to 10–15 or 30 minutes after 
inhalation of salbutamol 400 µg).
Statistical analysis
Given the different lengths of treatment in these studies, the 
pooled data from this patient population were presented in 
two ways. First, analyses of all data from all studies were 
used for adverse events, exacerbations, and deaths, with 
results adjusted for length of exposure and reported as 
incidence (number of events per patient-year of treatment). 
The indacaterol 150 µg dose was best represented in terms 
of patient numbers and treatment duration, and it was used 
as the index treatment group for determining the order of 
incidence of “common” adverse events. Second, data on the 
“acute” effects of treatment (pulse, blood pressure, the ECG-
derived QTc interval, plasma potassium, and blood glucose) 
were analyzed for the first 3 months of treatment (including 
any post-baseline measurement) and were not adjusted for 
exposure. The 3-month data were also used for the analysis 
of adverse events by severity. One advantage of analyzing 
these data over the 3-month period (and one reason why 
adjustment for exposure is not required) is that the studies 
included had a minimum duration of 3 months. In addition, 
since these acute effects are determined from data collected 
at discrete time points (in contrast to adverse events, which 
could occur at any time during the study), the authors believe 
that it is not valid to correct these data for exposure.
Risk ratios for adverse events (active versus placebo) 
and 95% confidence intervals (CI) were obtained by Poisson 
regression with treatment and study in the model as class 
effects. The relative risk of death (active versus placebo) 
and 95% CI were calculated through Poisson regression with 
treatment as a factor in the model. For the MACE analysis, 
the hazard ratios versus placebo were obtained from a Cox 
proportional hazards regression model stratified by study 
and country with treatment, inhaled corticosteroid (ICS) 
use, study, and seven baseline cardiovascular risk factors 
included as covariates. (Cardiovascular risk factors were: 
baseline age $65 years, current smoker, cardio- or cerebro-
vascular condition, hypertension, hyperlipidemia, diabetes 
mellitus, and body mass index .30 kg/m2.) Hazard ratios   
for time to first acute respiratory serious adverse event were 
events were adjudicated independently in a blinded fash-
ion to determine which were primarily cardiac in nature, 
and these were included in both broad and custom MACE 
searches.
A “serious adverse event” was defined as an event that: 
was fatal or life threatening, resulted in persistent or signifi-
cant disability/incapacity, constituted a congenital anomaly/
birth defect, required inpatient hospitalization or prolonga-
tion of existing hospitalization (with certain exceptions), 
or was medically significant (an event that jeopardized the 
patient or required medical or surgical intervention to prevent 
one of the outcomes listed above). All deaths occurring after 
intake of the first dose of the study drug up to and includ-
ing 30 days after the patient’s last dose of study drug were 
included in the present analysis.
An additional analysis of serious adverse events was 
conducted using a composite endpoint of acute respiratory 
events resulting in hospitalization, intubation, or death.17 
Data for all serious adverse events occurring in patients 
in studies of at least 7 days in length (including studies 
in COPD and asthma) were supplied to an adjudication 
  committee of five pulmonologists who were independent 
of the manufacturers of indacaterol. The committee, which 
was blinded to treatment, reviewed details of each event to 
determine if it was due to an acute worsening of underlying 
COPD or asthma or to pneumonia. Results of the 23 studies 
conducted in COPD patients are reported here.
Since systemic β2-adrenoceptor stimulation may cause 
tachycardia and various metabolic effects,18 variables that 
reflect the effect of treatment on systemic β2-adrenoceptors 
are also presented, including plasma potassium, blood 
glucose, and the electrocardiogram (ECG)-derived QTc 
interval. Measurements of vital signs (pulse and blood 
pressure), ECG, plasma potassium, and blood glucose levels 
were made at baseline and at intervals during the treatment 
periods.
Early in the indacaterol clinical development program, it 
was noticed that some patients had a transient cough shortly 
after indacaterol inhalation. Later, and in the studies included 
here, this cough was monitored and its time to onset and 
duration recorded separately by investigators. The incidence 
of cough was also evaluated for possible associations, for 
example with bronchospasm or treatment discontinuation.
Patients
The studies had almost identical patient entry criteria. 
Patients were to be at least 40 years of age at screening, 
with a smoking history of 10–20 pack-years (depending on 
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obtained from a Cox regression model stratified by country 
and study, with treatment, age, baseline FEV1, and albuterol 
reversibility as factors and the interaction of treatment and 
age as covariates. The results for the indacaterol (all) group 
for risk of MACE event and death were based on a weighted 
(by size) average of the indacaterol doses.
The rate of COPD exacerbations was analyzed for the 
intent-to-treat population of patients, including all random-
ized patients who received at least one dose of study drug, 
analyzed according to the treatment to which they were 
randomized. The analysis used a negative binomial model 
including terms for treatment, smoking status, ICS use, base-
line COPD exacerbation history, baseline FEV1 reversibility 
components, study, and country. As exacerbation rate was an 
efficacy endpoint, the above-therapeutic indacaterol 600 µg 
dose was not included in this analysis. All these methods take 
account of the varying exposure lengths across the studies.
Results for sitting pulse, sitting blood pressure, QTc 
interval, plasma potassium, and blood glucose are presented 
as percentages of patients with notable values and as least 
squares means and associated 95% CI.
Results
Patients and exposure to treatment
Table 1 shows the length of time for which patients were 
exposed to study drugs. The 75 µg dose of indacaterol was 
only evaluated in studies of 12 weeks’ duration. Patients in 
all treatment groups had a mean age of 63–64 years and a 
mean duration of COPD of 7 years. FEV1% predicted was 
53%–55% across the treatment groups. Other baseline char-
acteristics of the patients are summarized in Table 2. Treat-
ment groups were reasonably well matched apart from ethnic 
origin, notably the proportion of Asian patients. Of note, 
approximately 40% of patients had three or more pre-existing 
cardiovascular risk factors and approximately 20% had a con-
comitant cardio- or cerebrovascular condition. Completion 
rates and reasons for withdrawal from the treatment groups 
are shown in Table S2.
Adverse events
Table 3 shows the overall adverse events and the most com-
mon adverse events ($0.05 incidence in the indacaterol 
150 µg group), arranged within their respective system organ 
classes. The five most common events with indacaterol were 
COPD worsening, nasopharyngitis, headache, cough and 
upper respiratory tract infection (URTI). COPD worsening 
was the most common event in all treatment groups. The 
incidence of COPD worsening with all active treatments was 
lower than with placebo, and the upper 95% of the CIs for 
the associated relative risks were all ,1, indicating a signifi-
cant reduction compared with placebo. For the other most 
common adverse events, there were no consistent increases 
or decreases in incidence with indacaterol compared with 
placebo, and no relationship to indacaterol dose. For muscle 
spasms, the sixth most common adverse event, the incidence 
was increased relative to placebo with indacaterol 150, 300, 
and 600 µg, although, again, this did not appear to be related 
to dose.
Severity of adverse events was analyzed up to the 3-month 
time point. Those events occurring most commonly with 
indacaterol were generally mild or moderate in severity, 
with a minority recorded as severe: COPD worsening, 9.0% 
of cases; nasopharyngitis, 1.6%; headache, 4.8%; cough,   
1.8%; URTI, 1.5%, and muscle spasms, 9.9%.
Besides headache and muscle spasms (Table 3), the 
incidence of other adverse events commonly associated with 
β2-agonist class effects, including insomnia, anxiety, tremor, 
palpitations, and tachycardia, are presented in Table 4. There 
Table 1 Duration of exposure to study drug after randomization
IND 75  
n = 449
IND 150  
n = 2611
IND 300  
n = 1157
IND 600  
n = 547
FOR  
n = 556
SLM  
n = 895
TIO  
n = 1214
PBO  
n = 2012
Exposure, days,  
mean (SD)
85.5  
(25.81)
120.3  
(74.61)
232.7  
(123.27)
263.4  
(135.27)
260.3  
(133.46)
112.2  
(51.45)
107.7  
(49.36)
167.7  
(115.93)
Median (range) 85.0  
(2–179)
85.0  
(1–385)
183.0  
(1–420)
364.0  
(1–407)
363.0  
(1–397)
85.0  
(1–215)
85.0  
(1–208)
176.0  
(1–403)
Patient-years 105.1 859.7 737.0 394.5 396.2 274.9 358.0 923.6
Exposure, % of patients
  , 1 mo 4.5 4.6 6.2 5.7 5.2 4.9 5.1 9.1
    1–,3 mo 75.5 60.3 13.7 13.0 12.2 60.1 61.9 34.7
    3–,6 mo 20.0 9.8 11.4 15.9 18.2 9.3 13.3 10.1
    6–,12 mo 0 22.3 46.6 34.9 34.2 25.7 19.8 34.2
  $ 12 mo 0 3.0 22.1 30.5 30.2 0 0 11.9
Abbreviations: IND, indacaterol; FOR, formoterol; SLM, salmeterol; TIO, tiotropium; PBO, placebo; SD, standard deviation; mo, month(s); n, number.
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Table 2 Patients’ baseline and demographic characteristics and coexisting cardiovascular risk factorsa
IND 75  
n = 449
IND 150  
n = 2611
IND 300  
n = 1157
IND 600  
n = 547
FOR  
n = 556
SLM  
n = 895
TIO  
n = 1214
PBO  
n = 2012
Age (%)
 , 65 years 53.2 52.5 49.6 53.4 50.7 53.7 54.0 52.3
  65–,75 years 34.1 36.0 37.5 36.4 36.9 35.4 35.8 36.8
 $ 75 years 12.7 11.5 12.9 10.2 12.4 10.8 10.3 10.9
Males (%) 55.2 69.5 78.5 73.3 75.2 74.2 66.5 71.4
Race (%)
  Caucasian 92.2 77.6 66.7 92.0 91.9 82.2 91.4 74.7
  Black 4.2 2.1 1.1 1.1 0.5 1.2 1.5 1.9
  Asian 2.5 17.7 30.1 2.7 2.3 13.4 4.3 20.6
  Other 1.1 2.6 2.1 4.2 5.2 3.1 2.8 2.8
Severity of COPD (%)
  GOLD stage II or less 63.0 58.7 55.7 55.8 55.6 55.0 59.9 55.2
  GOLD stage III or worse 37.0 41.3 44.3 44.1 43.9 45.0 40.1 44.7
ICS use (current) (%) 41.7 43.6 42.4 48.8 50.4 45.9 48.5 41.0
Ex/current smoker (%) 52.1/47.9 56.5/43.5 60.9/39.5 58.7/41.3 59.2/40.8 55.2/44.8 55.7/44.3 57.1/42.9
Pack-years (mean [SD]) 53.9 (26.82) 44.5 (22.69) 48.4 (33.21) 53.0 (60.43) 49.8 (54.60) 43.2 (21.88) 44.6 (22.09) 49.0 (42.03)
No. of CV risk factorsa (%)
 0 3.3 7.1 9.0 6.8 7.9 6.7 6.7 7.2
 1 17.4 23.2 27.4 25.6 23.2 26.9 21.6 26.6
 2 31.0 28.2 28.4 28.0 28.4 25.3 29.4 26.4
  3 or more 48.3 41.5 35.2 39.7 40.5 41.1 42.3 39.8
Concomitant CCV condition 22.5 18.2 16.9 20.8 20.5 20.2 19.9 19.0
Note: aCV risk factors were: age $65, current smoker, CCV condition, hypertension, hyperlipidemia, diabetes mellitus, and body mass index .30 kg/m2 at baseline.
Abbreviations: IND, indacaterol; FOR, formoterol; SLM, salmeterol; TIO, tiotropium; PBO, placebo; COPD, chronic obstructive pulmonary disease; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; CV, cardiovascular; CCV, cardio- or cerebrovascular; n, number.
were no consistent patterns of significant changes caused by 
active compared with placebo treatment. The only events 
recorded as severe (from the 3-month data) for indacaterol 
doses combined were one event each of anxiety, palpitations, 
and tachycardia. None of the insomnia or tremor events was 
considered severe.
Major adverse cardiovascular events 
(MACE) analysis
Results of the MACE analysis are shown in Table 5. For both 
the broad and the more focused custom MACE categories, 
incidence was numerically lower with all active treatments 
than with placebo. Hazard ratios versus placebo (Figure 1) 
showed a nonsignificant reduction with all active treatments 
apart from tiotropium, which was nonsignificantly increased. 
There was no relationship with indacaterol dose.
Deaths and serious adverse events
The number of deaths adjusted per patient-year (Table 6) 
was lower with all indacaterol dose groups and with the other 
active treatments, than with placebo, and there was no rela-
tionship with indacaterol dose. Fourteen deaths occurred in 
the placebo group, with causes listed as: COPD exacerbation 
(1), cardiac arrest (1), cardiorespiratory arrest (1), myocardial 
infarction or possible myocardial infarction (3), sudden 
death (3), ruptured aortic aneurysm (2), multiorgan failure 
(1), accidental fall (1), and unknown (1). There were four 
deaths in the indacaterol 150 µg group, none of which was 
suspected of being treatment related (causes were: sudden 
death, cardiac arrest and death, cardiopulmonary failure 
and gastric cancer, and acute myocardial infarction). There 
were two deaths in the indacaterol 300 µg group (one due 
to cardiac arrest, one due to myocardial infarction), after 87 
and 232 days of treatment, both of which were suspected to 
be treatment related. One death due to a COPD exacerba-
tion after 189 days of indacaterol 600 µg treatment was also 
suspected to be treatment related. The relative risk of death 
compared with placebo (Figure 2) was reduced with LABA 
treatment, with P-values that were significant (all indacaterol 
doses combined, P = 0.008; salmeterol, P = 0.045) or close 
to significant (indacaterol 300 µg, P = 0.054; indacaterol 
150 µg, P = 0.068), excluding the 75 µg group in which no 
deaths occurred. Relative risks versus placebo for formoterol 
and tiotropium were slightly higher than those with the other 
active treatments.
The most commonly occurring serious adverse events 
are listed in Table 6. The overall incidence of serious 
adverse events was similar (and numerically lower) with 
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Table 3 Incidence (events per patient-year) of most common adverse events (includes all events with $0.05 incidence in any indacaterol 
group), adjusted for length of time on treatment, sorted by (a) primary system organ class and (b) preferred term, with relative risks 
versus placebo and 95% CI
IND 75  
n = 449
IND 150  
n = 2611
IND 300  
n = 1157
IND 600  
n = 547
FOR  
n = 556
SLM  
n = 895
TIO  
n = 1214
PBO  
n = 2012
Total patient years 105.06 859.72 736.97 394.49 396.21 274.93 357.97 923.60
AE episodes/patient-year 5.39 4.10 3.92 3.56 2.95 3.02 4.45 3.88
Respiratory, thoracic and  
mediastinal disorders (total)
1.26 0.93 1.05 0.88 0.80 0.69 1.10 1.07
COPD worsening 0.41 0.46 0.55 0.54 0.59 0.35 0.48 0.67
  Relative risk (95% CI) 0.66 
(0.47, 0.93)
0.76 
(0.66, 0.88)
0.80 
(0.70, 0.91)
0.74 
(0.63, 0.88)
0.75 
(0.64, 0.89)
0.71 
(0.54, 0.92)
0.64 
(0.52, 0.79)
– in patients on ICS 0.54 0.64 0.74 0.68 0.64 0.48 0.63 0.79
– in patients not on ICS 0.32 0.33 0.40 0.40 0.46 0.24 0.35 0.58
Cough 0.30 0.17 0.16 0.12 0.07 0.08 0.16 0.12
  Relative risk (95% CI) 1.38 
(0.86, 2.22)
1.17  
(0.88,1.55)
1.52 
(1.15, 2.00)
1.29 
(0.88, 1.89)
0.75 
(0.48, 1.18)
0.87 
(0.49, 1.52)
0.83 
0.57, 1.21)
Dyspnea 0.10 0.06 0.05 0.06 0.04 0.06 0.08 0.08
  Relative risk (95% CI) 0.72 
(0.34, 1.52)
0.60 
(0.40, 0.91)
0.68 
(0.45, 1.04)
0.98 
(0.59, 1.62)
0.58 
(0.32, 1.06)
0.52 
(0.27, 1.00)
0.59 
(0.35, 1.01)
Oropharyngeal pain 0.11 0.05 0.05 0.02 0.02 0.04 0.08 0.03
  Relative risk (95% CI) 2.96 
(1.18, 7.43)
1.86 
(1.07, 3.22)
1.60 
(0.93, 2.75)
1.09 
(0.48, 2.51)
0.84 
(0.34, 2.08)
1.98 
(0.74, 5.30)
2.47 
(1.27, 4.83)
Infections and infestations (total) 1.25 0.94 1.07 0.97 0.77 0.66 1.13 0.96
Nasopharyngitis 0.27 0.22 0.27 0.32 0.22 0.19 0.24 0.22
  Relative risk (95% CI) 1.52 
(0.94, 2.46)
1.21 
(0.96, 1.51)
1.20 
(0.98, 1.47)
1.28 
(1.01, 1.64)
0.89 
(0.68, 1.17)
1.26 
(0.86, 1.85)
1.14 
(0.84, 1.55)
Upper RTI (5) 0.17 0.11 0.13 0.09 0.07 0.03 0.14 0.12
  Relative risk (95% CI) 1.05 
(0.59, 1.85)
0.91 
(0.68, 1.23)
0.96 
(0.72, 1.27)
1.07 
(0.71, 1.62)
0.85 
(0.55, 1.33)
0.46 
(0.19, 1.12)
0.95 
(0.64, 1.39)
Upper RTI bacterial 0.06 0.06 0.09 0.09 0.08 0.02 0.05 0.09
  Relative risk (95% CI) 0.65 
(0.25, 1.67)
0.77 
(0.50, 1.18)
0.89 
(0.64, 1.24)
0.71 
(0.47, 1.07)
0.60 
(0.39, 0.94)
0.19 
(0.06, 0.57)
0.53 
(0.29, 0.98)
Lower RTI 0.02 0.06 0.09 0.10 0.08 0.09 0.06 0.09
  Relative risk (95% CI) 0.21 
(0.05, 0.90)
0.79 
(0.53, 1.18)
0.83 
(0.60, 1.16)
0.85 
(0.56, 1.28)
0.69 
(0.45, 1.07)
1.50 
(0.81, 2.77)
0.62 
(0.36, 1.07)
Influenza 0.04 0.05 0.05 0.07 0.04 0.03 0.06 0.04
  Relative risk (95% CI) 1.57 
(0.49, 5.05)
1.08 
(0.62, 1.91)
1.31 
(0.82, 2.09)
1.33 
(0.77, 2.30)
0.76 
(0.40, 1.44)
1.11 
(0.43, 2.90)
0.70 
(0.36, 1.40)
Bronchitis 0.12 0.05 0.06 0.06 0.04 0.03 0.06 0.07
  Relative risk (95% CI) 1.06 
(0.54, 2.12)
0.75 
(0.48, 1.17)
0.97 
(0.65, 1.45)
0.91 
(0.54, 1.54)
0.69 
(0.39, 1.23)
1.18 
(0.42, 3.39)
0.52 
(0.30, 0.91)
Viral upper RTI 0.05 0.05 0.06 0.03 0.04 0.02 0.04 0.05
  Relative risk (95% CI) 0.84 
(0.29, 2.41)
1.21 
(0.76, 1.94)
1.34 
(0.86, 2.11)
0.57 
(0.28, 1.18)
0.85 
(0.45, 1.60)
0.41 
(0.15, 1.14)
0.67 
(0.33, 1.35)
Nervous system disorders (total) 0.47 0.34 0.20 0.22 0.17 0.25 0.33 0.23
Headache 0.33 0.18 0.07 0.11 0.08 0.14 0.18 0.10
  Relative risk (95% CI) 2.34 
(1.46, 3.76)
1.11 
(0.80, 1.53)
0.67 
(0.47, 0.95)
1.09 
(0.73, 1.63)
0.77 
(0.50, 1.204)
0.78 
(0.47, 1.29)
0.90 
(0.61, 1.32)
Musculoskeletal and connective 
tissue disorders (total)
0.41 0.37 0.31 0.32 0.25 0.26 0.33 0.28
Muscle spasms 0.06 0.10 0.07 0.11 0.05 0.06 0.02 0.04
  Relative risk (95% CI) 1.30 
(0.47, 3.59)
2.42 
(1.58, 3.71)
2.08 
(1.34, 3.24)
3.48 
(2.10, 5.78)
1.69 
(0.93, 3.04)
1.26 
(0.63, 2.54)
0.66 
(0.29, 1.49)
Arthralgia 0.10 0.05 0.04 0.03 0.02 0.02 0.03 0.03
  Relative risk (95% CI) 2.14 
(0.88, 5.20)
1.40 
(0.79, 2.47)
1.32 
(0.76, 2.30)
1.32 
(0.64, 2.74)
0.71 
(0.29, 1.71)
0.42 
(0.14, 1.27)
0.61 
(0.27, 1.38)
Back pain 0.06 0.05 0.04 0.05 0.07 0.06 0.06 0.06
  Relative risk (95% CI) 1.05 
(0.39, 2.78)
0.86 
(0.55, 1.35)
0.73 
(0.46, 1.16)
0.84 
(0.47, 1.51)
1.20 
(0.71, 2.03)
1.18 
(0.56, 2.47)
0.80 
(0.44, 1.47)
Abbreviations: IND, indacaterol; FOR, formoterol; SLM, salmeterol; TIO, tiotropium; PBO, placebo; AE, adverse event; COPD, chronic obstructive pulmonary disease;   
CI, confidence interval; ICS, inhaled corticosteroids; RTI, respiratory tract infection; n, number.
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all indacaterol groups compared with placebo. The most 
common serious adverse event was COPD worsening, 
which was numerically lower with indacaterol (all doses) 
than   placebo; as expected, given the definition of a serious 
adverse event, most of these episodes led to hospitaliza-
tion. Comparing subgroups of patients receiving ICS or 
not at study entry, the incidence of COPD worsening as a 
serious adverse event was similar or lower in the non-ICS 
users compared with ICS users in the indacaterol 75 µg, 
150 µg, and 300 µg and salmeterol groups, and slightly 
higher in the non-ICS users compared with the ICS users 
with indacaterol 600 µg, formoterol, tiotropium, and 
placebo. Serious adverse events in the categories “infec-
tions and infestations” and “cardiac disorders” generally 
occurred at a similar incidence in active and placebo treat-
ment groups, with no relationship between incidence and 
indacaterol dose.
Rates of acute respiratory serious adverse events (as 
adjudicated by the blinded independent committee) were not 
significantly increased with the bronchodilator treatments 
compared with placebo (Table 7). None of the active 
treatments was associated with a significant increase in risk 
relative to placebo.
Rate of COPD exacerbations
Rates of COPD exacerbations were significantly reduced 
relative to placebo with all the active treatments (Figure 3). 
There were no statistically significant differences between 
active treatments.
Cough following indacaterol inhalation
In the “all data” analysis, the mean percentage of attended 
visits at which patients experienced cough after inhalation 
of indacaterol ranged from 14.1% to 18.4% across the inda-
caterol dose groups, compared with 2% in the placebo group, 
increasing slightly with increasing indacaterol dose. For the 
majority of patients, the cough started within 15 seconds of 
inhalation and lasted for #15 seconds; the median duration 
in the indacaterol groups at each visit was #6 seconds. There 
Table 4 Incidence (events per patient-year) of selected adverse events commonly associated with β2-adrenoceptor mediated effects, 
adjusted for length of time on treatment
IND 75  
n = 449
IND 150  
n = 2611
IND 300  
n = 1157
IND 600  
n = 547
FOR  
n = 556
SLM  
n = 895
TIO  
n = 1214
PBO  
n = 2012
Total patient years 105.06 859.72 736.97 394.49 396.21 274.93 357.97 923.60
Insomnia 0.02 0.02 0.01 0.02 0.02 0.05 0.02 0.03
  Relative risk (95% CI) 0.60 
(0.13, 2.82)
0.47 
(0.24, 0.94)
0.28 
(0.12, 0.65)
1.14 
(0.42, 3.11)
1.68 
(0.69, 4.07)
1.86 
(0.57, 6.01)
0.49 
(0.19, 1.24)
Anxiety 0.02 0.02 0.01 0.02 0.01 0.02 0.01 0.02
  Relative risk (95% CI) 0.48 
(0.10, 2.36)
0.79 
(0.32, 1.97)
0.88 
(0.36, 2.15)
1.46 
(0.50, 4.26)
0.72 
(0.19, 2.72)
0.71 
(0.16, 3.14)
0.19 
(0.04, 0.92)
Tremora 0 0.01 0.01 0.03 0.02 0.01 0.01 0.01
Palpitations 0.01 0.01 0.01 0.01 0 0.02 0.02 0.01
  Relative risk (95% CI) 0.98 
(0.09, 10.6)
0.22 
(0.05, 0.96)
0.69 
(0.29, 1.64)
0.27 
(0.06, 1.27)
0.14 
(0.02, 1.08)
0.54 
(0.08, 3.83)
0.83 
(0.19, 3.70)
Tachycardia 0.01 0 0.01 0.01 0.01 0.01 0.01 0.01
  Relative risk (95% CI) 1.15 
(0.10, 13.6)
0.73 
(0.12, 4.26)
0.87 
(0.31, 2.42)
0.46 
(0.12, 1.77)
0.30 
(0.06, 1.46)
2.77 
(0.18, 41.90)
1.43 
(0.30, 6.91)
Note: aThere are no risk ratios for tremor as the model did not converge and the output was unreliable.
Abbreviations: IND, indacaterol; FOR, formoterol; SLM, salmeterol; TIO, tiotropium; PBO, placebo; CI, confidence interval; n, number.
Table 5 Major adverse cardiovascular events (MACE) episodes
IND 75  
n = 449
IND 150  
n = 2611
IND 300  
n = 1157
IND 600  
n = 547
FOR  
n = 556
SLM  
n = 895
TIO  
n = 1214
PBO  
n = 2012
Total patient years 105.06 859.72 736.97 394.49 396.21 274.93 357.97 923.60
Broad MACE
  Patients with $1 event, n (%) 4 (0.89) 21 (0.80) 8 (0.69) 6 (1.10) 7 (1.26) 7 (0.78) 11 (0.91) 29 (1.44)
  Events per patient-year (n) 0.04 0.04 0.01 0.02 0.02 0.03 0.04 0.04
Custom MACE
  Patients with $1 event, n (%) 1 (0.22) 14 (0.54) 5 (0.43) 3 (0.55) 4 (0.72) 4 (0.45) 4 (0.33) 19 (0.94)
  Events per patient-year (n) 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.02
Abbreviations: IND, indacaterol; FOR, formoterol; SLM, salmeterol; TIO, tiotropium; PBO, placebo; n, number.
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was no apparent association between the cough following 
indacaterol inhalation and decreased FEV1 or COPD exac-
erbations, or with reasons for or rates of withdrawal from 
the studies.
β2-adrenoceptor-mediated systemic 
effects
Plasma potassium, blood glucose, and QTc interval values 
were assessed after 3 months’ treatment (Table 8). The 
percentages of patients with notably low values of plasma 
potassium were not higher with any active treatment than 
with placebo, and there was no relationship between inci-
dence of notable values and indacaterol dose. High blood 
glucose levels occurred at a similar rate in active and pla-
cebo treatment groups apart from a slightly higher rate in 
the indacaterol 600 µg and salmeterol groups. The rate of 
high absolute values of QTc interval tended to be higher 
than placebo with most of the active treatment groups, but 
values .500 ms were rare overall (reported in two patients 
each in the indacaterol 150 µg and tiotropium groups). 
Increases from baseline in QTc interval of .60 ms were 
less common among indacaterol-treated patients than those 
in the placebo group. Mean differences for these variables 
compared with placebo are shown in Figure 4 and, although 
CIs occasionally failed to cross zero, the differences were 
small and clinically insignificant.
Vital signs
The percentages of patients with notably fast or slow pulse 
and high or low values of blood pressure (Table 8) were 
generally similar between with active treatments and   placebo. 
Small differences in mean values between active and placebo 
treatments and a trend to increasing pulse rate and decreasing 
blood pressure with increasing indacaterol dose were clini-
cally insignificant (Figure 4).
Discussion
It is important to evaluate carefully the safety of any new 
drug for the long-term treatment of COPD, given that many 
patients are elderly and often have several comorbidities 
treated with multiple concomitant medications.19 The present 
study examines a relevant population of patients of whom 
about 50% were aged . 65 years, with approximately 40% 
having three or more cardiovascular risk factors, including 
conditions such as hypertension and diabetes mellitus. The 
pooled patient population provided a substantial body of 
data and maximized exposure to study treatments, allowing a 
more robust comparison of treatment effects compared with 
single studies. The studies had very similar entry criteria, 
and outcomes were defined and evaluated in the same way 
across the studies.
Another important reason for examining the safety of a 
once-daily β2-agonist bronchodilator is the history of safety 
concerns with the twice-daily β2-agonists salmeterol and 
formoterol when used in asthma; specifically, the reported 
increased risk of asthma-related death and hospitalizations, 
which is generally thought to be mitigated by the concomitant 
use of ICS.20–22 While indacaterol is indicated only for use in 
COPD patients, the present data allow the examination of 
similar outcomes, for example, exacerbations of COPD and 
risks for death or hospitalization due to worsening of COPD. The 
risk of COPD worsening as an adverse event was significantly 
reduced with indacaterol compared with placebo. Similarly, 
the incidence of COPD worsening as a serious adverse event, 
including the subset of events leading to hospitalization, was 
numerically lower in all indacaterol treatment groups compared 
with placebo. There was also a general pattern for a lower 
A. Broad MACE
Indacaterol (all)
Indacaterol 75 µg
Indacaterol 150 µg
Indacaterol 300 µg
Indacaterol 600 µg
Formoterol
Salmeterol
01234
0123
Hazard ratio (95% Cl)
456
B. Custom MACE
Indacaterol (all)
Indacaterol 75 µg
Indacaterol 150 µg
Indacaterol 300 µg
Indacaterol 600 µg
Formoterol
Salmeterol
Tiotropium
Tiotropium
Figure 1 Risk of major adverse cardiovascular events (MACE) (myocardial infarction, 
stroke and cardiovascular death) relative to placebo, adjusted for length of time on 
treatment. (A) “Broad MACE” includes all preferred terms relating to myocardial 
infarction, cerebrovascular events, and nervous system hemorrhages; (B) “custom 
MACE” is a more focused subset of broad MACE including those preferred terms 
best describing myocardial infarction and stroke. (For the terms in each category, 
see Tables S3 and S4 in Supplementary material.)
Abbreviation: CI, confidence interval.
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incidence of COPD worsening as an adverse or serious adverse 
event in patients not receiving concomitant ICS (ie, who were 
receiving LABA monotherapy) compared with those who were 
receiving ICS. This is compatible with the GOLD guidelines 
that recommend patients with frequent exacerbations should 
be treated with ICS.1
The number of deaths during indacaterol treatment 
was extremely low, and the relative risk of all-cause death 
was reduced with indacaterol relative to placebo. These 
findings were borne out in the independently adjudicated 
analysis of all serious adverse events, which showed no 
Table 6 Deaths and serious (fatal and nonfatal) adverse events, with listing of most common serious adverse events (incidence $ 0.005 
per patient-year in indacaterol 150 µg group), adjusted for length of time on treatment
IND 75  
n = 449
IND 150  
n = 2611
IND 300  
n = 1157
IND 600  
n = 547
FOR  
n = 556
SLM  
n = 895
TIO  
n = 1214
PBO  
n = 2012
Total patient years 105.06 859.72 736.97 394.49 396.21 274.93 357.97 923.60
Deaths (n) 0 4 2 1 4 1 4 14
Deaths (n per patient year) 0 0.01 0 0 0.01 0 0.01 0.02
Serious adverse events (fatal  
and nonfatal) (n per patient year)
0.25 0.24 0.24 0.21 0.32 0.18 0.33 0.27
    Respiratory, thoracic and  
mediastinal disorders (total)
0.07 0.05 0.09 0.04 0.12 0.06 0.06 0.09
    COPD worsening 0.05 0.05 0.06 0.03 0.10 0.04 0.04 0.07
    – leading to hospitalization 0.05 0.05 0.06 0.03 0.09 0.04 0.04 0.06
    – in patients on ICS 0.05 0.07 0.08 0.03 0.09 0.05 0.04 0.08
    – in patients not on ICS 0.05 0.03 0.04 0.04 0.11 0.03 0.04 0.05
  Infections and infestations (total) 0.05 0.04 0.04 0.02 0.08 0.04 0.05 0.05
    Pneumonia 0.02 0.01 0.01 0.01 0.02 0.01 0.02 0.01
    Lower RTI 0 0.01 0 0.01 0.01 0.01 0 0.01
    URTI bacterial 0.01 0.01 0 0 0.01 0.01 0 0.01
  Cardiac disorders (total) 0.04 0.03 0.03 0.03 0.02 0.03 0.05 0.03
    Angina pectoris 0.01 0.01 0 0 0 0 0 0
    Acute myocardial infarction 0 0.01 0 0 0 0 0 0
    Atrial fibrillation 0.01 0.01 0.01 0 0 0 0.01 0.01
Abbreviations:  IND,  indacaterol;  FOR,  formoterol;  SLM,  salmeterol;  TIO,  tiotropium;  PBO,  placebo;  COPD,  chronic  obstructive  pulmonary  disease;  ICS,  inhaled 
corticosteroids; RTI, respiratory tract infection; URTI, upper RTI; n, number.
0123
Relative risk (95% Cl)
89
Indacaterol (all)
Indacaterol 75 µg (None)
Indacaterol 150 µg
Indacaterol 300 µg
Indacaterol 600 µg
Formoterol
Salmeterol
Tiotropium
Figure 2 Risk of death relative to placebo, adjusted for length of time on treatment.
Abbreviation: CI, confidence interval.
significant increase in risk for the acute respiratory events 
leading to hospitalization, intubation, or death. Thus, LABA 
monotherapy with indacaterol in COPD was not associated 
with any increase in deaths, COPD worsening adverse events, 
serious adverse events, or hospitalizations. Indeed, the rate 
of COPD exacerbations, within the strict definition of this 
event when analyzed in the intent-to-treat population, was 
significantly reduced relative to placebo with indacaterol, the 
other LABAs, and with tiotropium.
Many of the common adverse events occurred with a simi-
lar incidence in the indacaterol and placebo groups and reflect 
the typical signs and symptoms of COPD itself. The majority 
of events, such as nasopharyngitis, cough, oropharyngeal 
pain, muscle spasms, arthralgia, and influenza, were mild or 
moderate in severity in all or a large majority of cases in each 
study. The incidence of muscle spasms was notably higher 
with the LABA treatments than with placebo, which may be 
related to stimulation of skeletal muscle β2-adrenoceptors. 
While the analysis of tremor did not yield a risk ratio for 
statistical reasons, the risk ratios for other “typical” β2-class 
effects of headache, insomnia, anxiety, palpitations, and 
tachycardia were not increased with indacaterol doses of 
150 and 300 µg compared with placebo, and were rarely 
severe. Results for QTc interval, plasma potassium, and 
blood glucose showed no clinically significant changes with 
indacaterol treatment.
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In addition to the serious cases of COPD worsening 
discussed above, the incidence of serious adverse events was 
generally similar with active and placebo treatments, and 
again reflected typical disease manifestations in events such 
as pneumonia and respiratory tract infections. The overall 
incidence of serious adverse events in the category of cardiac 
disorders was similar between indacaterol and placebo.
Cardiovascular disorders were explored in more detail in 
the MACE analysis, in which the nonsignificant reductions 
in hazard ratio relative to placebo showed no indication of an 
association with indacaterol treatment for either the broad or 
more focused definition of cardiovascular events. Worth and 
colleagues recently published their analysis of the cardiovas-
cular and cerebrovascular safety of indacaterol in a subset of 
the patients included in the current analysis, and also showed 
no potential for increased risks in these areas with indacaterol 
Table 7 Incidence (events per patient-year) of acute respiratory-related serious adverse events,a adjusted for length of time on treatment
IND 75  
n = 543
IND 150  
n = 2745
IND 300  
n = 1422
IND 600  
n = 584
IND DPIb  
n = 6615
FOR  
n = 556
SLM  
n = 1010
TIO  
n = 842
PBO  
n = 2484
Total patient-years 108.98 865.25 747.38 395.23 2381.78 396.21 279.64 179.39 940.98
Acute respiratory-
related events
0.06 0.05 0.07 0.04 0.06 0.10 0.04 0.04 0.06
  COPD-related 0.05 0.05 0.06 0.03 0.05 0.09 0.04 0.03 0.06
    Pneumonia- 
related
0.03 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.01
Hazard ratio  
(95% CI) vs placebo  
for time to first  
acute respiratory 
event
1.37 
(0.49, 3.78)
0.84 
(0.51, 1.40)
1.05 
(0.70, 1.59)
0.61 
(0.33, 1.13)
0.93 
(0.69, 1.24)
1.28 
(0.78, 2.09)
0.94 
(0.41, 2.12)
0.64 
(0.20, 2.07)
Notes: Data from randomized, blinded treatment arms in studies of 7 days’ duration or longer in patients with COPD; events were categorized by an independent 
adjudication committee who reviewed narratives for each event but who were blinded to treatment; adefined as events due to acute worsening of underlying condition 
and involving hospitalization (admission or emergency room visit .24 h in duration), intubation (endotracheal intubation for mechanical ventilation for treatment of acute 
hypoxemic or hypercapneic respiratory failure) or death; acute events could be classified as related to COPD or pneumonia (as shown) or asthma (no events classified as 
such); ball patients receiving indacaterol via single-dose dry powder inhaler (includes 179 patients receiving indacaterol doses of 18.75 and 37.5 µg in dose-ranging studies).
Abbreviations: IND, indacaterol; FOR, formoterol; SLM, salmeterol; TIO, tiotropium; PBO, placebo; COPD, chronic obstructive pulmonary disease; CI, confidence interval; 
n, number.
0.00 .5 1.0
Rate ratio (95% Cl)
1.5 2.0
Comparison vs placebo (n = 1770):
Indacaterol 75 µg (n = 445)
Indacaterol 150 µg (n = 1849)
Indacaterol 300 µg (n = 921)
Formoterol (n = 517)
Salmeterol (n = 327)
Tiotropium (n = 1201)
P = 0.0325
P < 0.001
P = 0.0019
P = 0.0016
P = 0.0073
P < 0.001
Figure 3 Rate of chronic obstructive pulmonary disease exacerbations compared 
with placebo over 12 months of treatment.
Abbreviation: CI, confidence interval.
treatment.23 Similar findings were reported for salmeterol 
using the large 3-year Towards a Revolution in COPD Health 
(TORCH) study database,24 which found no increase in car-
diovascular events (including serious and ischemic events and 
deaths) with salmeterol compared with placebo.
Few deaths occurred in any of the active treatment groups 
in the current analysis, and the number of deaths adjusted per 
patient-year was not increased with any of the LABA treat-
ments relative to placebo. The finding of no deaths among the 
indacaterol 75 µg group should be interpreted with caution, 
since most of the data came from two 12-week studies. A 
lack of association between LABA treatment and increased 
mortality in COPD patients has been reported by others. The 
TORCH study reported nonsignificant reductions with salme-
terol in all-cause deaths (hazard ratio versus placebo 0.879 
[95% CI 0.729–1.061]) and in COPD-related deaths (hazard 
ratio versus placebo 1.01 [95% CI 0.76–1.35]).25 This finding 
was repeated in a meta-analysis of the available literature 
with LABAs in COPD, which also found a nonsignificant 
reduction in deaths with a LABA versus placebo (risk ratio 
0.90 [95% CI 0.77, 1.06]).26 A large case-control study with 
more than 32,000 case patients found that LABA treatment 
was associated with significantly reduced odds of death (odds 
ratio 0.92 [95% CI 0.88–0.96]) and a nonsignificant reduc-
tion in respiratory or cardiovascular deaths (odds ratio 0.98 
[95% CI 0.89–1.09]) compared with no treatment or with a 
short-acting β2-agonist alone.27
There was no dose relationship with indacaterol in any 
of the categories of adverse events discussed above. Minor 
exceptions were seen with the cough following inhalation 
and with vital signs. However, the effects of indacaterol on 
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Table 8 Percentages of patients with notable values for potassium (low) and glucose (high), blood pressures, pulse, and QTc interval 
(prolonged) at any time postbaselinea during the first 3 months of treatment
IND 75 
n = 449
IND 150  
n = 2611
IND 300  
n = 1157
IND 600  
n = 547
FOR  
n = 556
SLM  
n = 895
TIO  
n = 1214
PBO  
n = 2012
Potassium ,3.0 mmol/L 0.2 0.1 0.2 0 0 0.2 0 0.2
Glucose .9.99 mmol/L 4.9 4.0 5.1 6.4 4.7 5.5 3.5 5.4
Systolic blood pressure – highb 0.5 0.6 0.9 2.0 1.1 0.5 1.0 1.1
Systolic blood pressure – lowc 0.9 0.5 1.4 1.1 1.1 0.9 0.6 1.1
Diastolic blood pressure – highd 1.6 0.6 0.6 0.9 0.5 0.7 1.6 1.0
Diastolic blood pressure – lowe 0.5 0.5 1.0 1.1 0.9 0.3 0.4 0.6
Pulse rate – highf 0.2 0.2 0.3 0.4 0.4 0.1 0.1 0.3
Pulse rate – lowg 1.3 0.6 0.5 0.2 0.4 0.3 0.7 1.1
QTc interval
 . 450 ms (males) or 470 ms (females) 4.0 2.7 4.0 4.6 3.4 1.0 3.4 2.7
 . 500 ms 0 0.1 0 0 0 0 0.2 0
  Increase from baseline 30–60 ms 7.1 6.0 7.5 6.9 6.5 4.7 6.2 5.3
  Increase from baseline .60 ms 0 0.1 0.1 0.2 0 0.3 0.1 0.3
Notes: aMeasured on Day 1 and after 12 weeks of treatment in one study, on Day 1 and after 2 and 12 weeks in five studies, on Day 1 and after 4 and 12 weeks in two 
studies, and on Day 1 and after 4, 8, and 12 weeks in two studies; one study measured ECG and vital signs on Day 1 and Weeks 2 and 12 and laboratory evaluations on 
Weeks 4 and 12; b$180 mmHg and increase from baseline by $20 mmHg, or .200 mmHg; c,75 mmHg, or #90 mmHg and decrease from baseline by $20 mmHg; d$105 
mmHg and increase from baseline by $15 mmHg, or .115 mmHg; e,40 mmHg, or #50 mmHg and decrease from baseline by $15 mmHg; f$120 bpm and increase from 
baseline by $15 bpm, or .130 bpm; g,40 bpm, or #50 bpm and decrease from baseline by $15 bpm.
Abbreviations: IND, indacaterol; FOR, formoterol; SLM, salmeterol; TIO, tiotropium; PBO, placebo; n, number.
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Figure 4 Mean (95% CI) differences from placebo in plasma potassium, blood glucose, QTc interval, sitting pulse and sitting systolic and diastolic blood pressure (BP) at 
1 hour post-dose after 3 months of treatment.
Abbreviations: IND, indacaterol; FOR, formoterol; SLM, salmeterol; TIO, tiotropium; CI, confidence interval.
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pulse and blood pressure were clinically insignificant and 
no cause for concern. The cough following inhalation of 
indacaterol was quite common but was not associated with 
bronchospasm, increased withdrawal rate, or loss of efficacy, 
and should therefore not be considered a safety concern.
One limitation of this study is the limited numbers of 
patients on comparator therapies. For example, the non-
significantly increased hazard ratios for MACE and death 
(Figures 1 and 2) with tiotropium should be viewed with 
caution. The FDA recently concluded that data did not 
support an increased risk of stroke, heart attack, or death 
associated with tiotropium dry powder inhaler.28   However, a 
recent meta-analysis did report an increased risk of mortal-
ity associated with the use of tiotropium taken via soft mist 
inhaler (a different formulation from that used in the studies 
included in this analysis).29 In the present analysis, tiotro-
pium was administered open label in 35% of the patients in 
this treatment group, which may have introduced an element 
of bias. The results for the analysis of exacerbations may also 
be affected by low patient numbers in some of the treatment 
groups; elsewhere, for example, formoterol has been shown 
not to reduce COPD exacerbations.30,31 These results should 
also be interpreted in light of the overall low rates of exac-
erbations in all the studies included in this analysis.
The two doses of indacaterol of 150 and 300 µg, as 
licensed in many countries, provided the majority of the 
indacaterol data for this analysis and the results in these two 
treatment groups are therefore the best guide for potential 
safety and tolerability. Overall, the results with indacaterol 
150 and 300 µg demonstrate a good profile of safety and 
tolerability that is comparable with the other evaluated long-
acting bronchodilators. Compared with these two doses, 
results with the 75 µg dose of indacaterol were occasionally 
anomalous but must be considered in the context that these 
data are less robust in terms of shorter length of treatment 
(maximum 12 weeks) and fewer patients exposed to this dose. 
However, in the two studies evaluating the 75 µg dose, safety 
and tolerability profiles were similar to placebo.12 The results 
with the higher dose of indacaterol, 600 µg given for 1 year,3 
demonstrate a satisfactory therapeutic index between efficacy 
and safety with indacaterol.
In conclusion, this study finds that indacaterol is not asso-
ciated with any significant safety concerns. Physicians choos-
ing to prescribe indacaterol as regular maintenance treatment 
for patients with moderate-to-severe COPD in the expectation 
of bronchodilation and improved clinical outcomes may also 
be reassured of its good safety and tolerability profile.
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Supplementary tables
Table S1 Details of the studies included in the safety evaluation
Length (weeks) Patients (n) Treatments ClinicalTrials.gov reference Reference
52 1732 Indacaterol 300 µg od 
Indacaterol 600 µg od 
Placebo 
Formoterol 12 µg bid
NCT00393458 3
26 1683 Indacaterol 150 µg od 
Indacaterol 300 µg od 
Placebo 
Open-label tiotropium 18 µg od
NCT00463567 4a
52 415 Indacaterol 150 µg od 
Indacaterol 300 µg od 
Placebo
NCT00677807 6a
26 1002 Indacaterol 150 µg od 
Salmeterol 50 µg bid 
Placebo
NCT00567996 5
12 416 Indacaterol 150 µg od 
Placebo
NCT00624286 2
12 1123 Indacaterol 150 µg od 
Salmeterol 50 µg bid
NCT00821093 10
12 1598 Indacaterol 150 µg od 
Tiotropium 18 µg od
NCT00900731 11
12 323 Indacaterol 75 µg od 
Placebo
NCT01072448 12
12 318 Indacaterol 75 µg od 
Placebo
NCT01068600 12
12 347 Indacaterol 150 µg od 
Indacaterol 300 µg od 
Placebo
NCT00794157 13
26 563 Indacaterol 150 µg od 
Indacaterol 300 µg od 
Placebo
NCT00792805 –
Note: aPatients in core and extension studies were not double counted in safety evaluation.
Abbreviations: od, once daily; bid, twice daily; n, number.
Table S2 Withdrawal rates and reasons for withdrawal
IND 75  
n = 449
IND 150  
n = 2611
IND 300  
n = 1157
IND 600 
n = 547
FOR  
n = 556
SLM  
n = 895
TIO  
n = 1214
PBO  
n = 2012
Total withdrawals 50 (11.1) 311 (11.9) 221 (19.1) 119 (21.8) 121 (21.8) 88 (9.8) 143 (11.8) 475 (23.6)
  Adverse event 22 (4.9) 123 (4.7) 73 (6.3) 34 (6.2) 44 (7.9) 28 (3.1) 44 (3.6) 134 (6.7)
  Withdrawal of consent 15 (3.3) 75 (2.9) 58 (5.0) 43 (7.9) 34 (6.1) 24 (2.7) 27 (2.2) 140 (7.0)
    Unsatisfactory therapeutic  
effect
2 (0.5) 11 (0.4) 27 (2.3) 9 (1.7) 13 (2.3) 4 (0.5) 12 (1.0) 85 (4.2)
  Protocol deviation 5 (1.1) 40 (1.5) 25 (2.2) 12 (2.2) 13 (2.3) 17 (1.9) 25 (2.1) 51 (2.5)
  Administrative problems 0 10 (0.4) 16 (1.4) 9 (1.7) 6 (1.1) 2 (0.2) 4 (0.3) 15 (0.8)
  Loss to follow-up 3 (0.7) 33 (1.3) 14 (1.2) 7 (1.3) 6 (1.1) 8 (0.9) 16 (1.3) 27 (1.3)
  Abnormal test procedure result 1 (0.2) 8 (0.3) 4 (0.4) 3 (0.6) 1 (0.2) 2 (0.2) 5 (0.4) 5 (0.3)
  Abnormal laboratory value 2 (0.5) 7 (0.3) 2 (0.2) 1 (0.2) 0 1 (0.1) 6 (0.5) 5 (0.3)
  Death 0 4 (0.2) 2 (0.2) 0 4 (0.7) 1 (0.1) 4 (0.3) 11 (0.6)
    No further requirement for  
study drug
0 0 0 1 (0.2) 0 0 0 1 (0.1)
  Not stated 0 0 0 0 0 0 0 1 (0.1)
  Inability to use the inhaler 0 0 0 0 0 1 (0.1) 0 0
Note: Data are n (%).
Abbreviations: IND, indacaterol; FOR, formoterol; SLM, salmeterol; TIO, tiotropium; PBO, placebo; n, number.
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Table S3 Preferred terms in the broad major adverse cardiovascular events (MACE) category
Central nervous system hemorrhages and cerebrovascular conditions*
Agnosia Hematomyelia Cerebellar ischemia
Amaurosis fugax Hemorrhage intracranial Cerebral arteriosclerosis
Angiogram cerebral abnormal Hemorrhagic cerebral infarction Cerebral artery embolism
Aphasia Hemorrhagic stroke Cerebral artery occlusion
Balint’s syndrome Hemorrhagic transformation stroke Cerebral artery stenosis
Carotid artery aneurysm Intracerebral hematoma evacuation Cerebral artery thrombosis
Carotid artery dissection Intracranial hematoma Cerebral infarction
Central pain syndrome Intraventricular hemorrhage Cerebral infarction fetal
Cerebral aneurysm ruptured syphilitic Intraventricular hemorrhage neonatal Cerebral ischemia
Cerebrovascular accident prophylaxis Meningorrhagia Cerebral revascularization synangiosis
Charcot–Bouchard microaneurysms Putamen hemorrhage Cerebral thrombosis
Diplegia Ruptured cerebral aneurysm Cerebral vasoconstriction
Dysarthria Spinal cord hemorrhage Cerebral venous thrombosis
Hemiparesis Spinal epidural hemorrhage Cerebrovascular accident
Hemiplegia Spinal hematoma Cerebrovascular disorder
Intra-cerebral aneurysm operation Stroke in evolution Cerebrovascular insufficiency
Intracranial aneurysm Subarachnoid hemorrhage Cerebrovascular spasm
Monoparesis Subarachnoid hemorrhage neonatal Cerebrovascular stenosis
Monoplegia Subdural hemorrhage Embolic cerebral infarction
Paralysis Subdural hemorrhage neonatal Embolic stroke
Paralysis flaccid Thalamus hemorrhage Ischemic cerebral infarction
Paraparesis Basal ganglia infarction Ischemic stroke
Paraplegia Basilar artery occlusion Lacunar infarction
Paresis Basilar artery stenosis Lateral medullary syndrome
Quadriparesis Basilar artery thrombosis Millard–Gubler syndrome
Quadriplegia Brain stem infarction Moyamoya disease
Red blood cells CSF positive Brain stem ischemia Post procedural stroke
Spastic paralysis Brain stem stroke Precerebral artery occlusion
Spastic paraplegia Brain stem thrombosis Reversible ischemic neurological deficit
Visual midline shift syndrome Capsular warning syndrome Spinal artery embolism
Basal ganglia hemorrhage Carotid arterial embolus Stroke in evolution
Brain stem hemorrhage Carotid arteriosclerosis Thalamic infarction
Brain stem stroke Carotid artery bypass Thrombotic cerebral infarction
Carotid aneurysm rupture Carotid artery disease Thrombotic stroke
Cerebellar hematoma Carotid artery insufficiency Transient ischemic attack
Cerebellar hemorrhage Carotid artery occlusion Vascular encephalopathy
Cerebral arteriovenous malformation hemorrhagic Carotid artery stenosis Vertebral artery occlusion
Cerebral hematoma Carotid artery stent insertion Vertebral artery stenosis
Cerebral hemorrhage Carotid artery thrombosis Vertebral artery thrombosis
Cerebral hemorrhage fetal Carotid endarterectomy Vertebrobasilar insufficiency
Cerebral hemorrhage neonatal Cerebellar artery occlusion Wallenberg syndrome
Cerebral microhemorrhage Cerebellar artery thrombosis Brachiocephalic artery occlusion
Cerebrovascular accident Cerebellar embolism Carotid artery stent removal
Cerebrovascular disorder Cerebellar infarction
Myocardial infarction*
Acute coronary syndrome Coronary artery thrombosis Papillary muscle infarction
Acute myocardial infarction Coronary bypass thrombosis Post procedural myocardial infarction
Blood creatine phosphokinase abnormal Electrocardiogram Q wave abnormal Postinfarction angina
Blood creatine phosphokinase increased Electrocardiogram ST segment abnormal Scan myocardial perfusion abnormal
Blood creatine phosphokinase MB abnormal Electrocardiogram ST segment elevation Silent myocardial infarction
Blood creatine phosphokinase MB increased Electrocardiogram ST-T segment elevation Troponin I increased
Cardiac enzymes increased Infarction Troponin increased
Coronary artery embolism Kounis syndrome Troponin T increased
Coronary artery occlusion Myocardial infarction Vascular graft occlusion
Coronary artery reocclusion Myocardial reperfusion injury
Notes: *Level 2 standardized Medical Dictionary of Regulatory Activities (MedDRA) query (SMQs) (subgroups of the “ischemic heart disease” and “cerebrovascular 
disorders” Level 1 SMQs, respectively) from MedDRA version 13.0.
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Table S4 Preferred terms in the custom major adverse cardiovascular events (MACE) category
Acute myocardial infarction Cerebrovascular accident Moyamoya disease
Basilar artery thrombosis Coronary artery thrombosis Myocardial infarction
Brain stem infarction Embolic cerebral infarction Papillary muscle infarction
Brain stem stroke Embolic stroke Post procedural myocardial
Brain stem thrombosis Hemorrhagic cerebral infarction Post procedural stroke
Carotid arterial embolus Hemorrhagic stroke Silent myocardial infarction
Carotid artery thrombosis Hemorrhagic transformation stroke Stroke in evolution
Cerebellar infarction Ischemic cerebral infarction Thalamic infarction
Cerebral artery embolism Ischemic stroke Thrombotic cerebral infarction
Cerebral artery thrombosis Lacunar infarction Thrombotic stroke
Cerebral infarction Cerebrovascular accident Wallenberg syndrome
Cerebral thrombosis Lateral medullary syndrome
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